ARS Pharmaceuticals
The Executive Director, Sales - West leads the national sales organization for the Western US, translating the neffy® brand strategy into field execution and driving revenue growth. This role involves building and sustaining a high-performing sales team, managing budgets, and collaborating with cross-functional teams to align priorities and optimize resource allocation. The position requires strategic input into commercial leadership decisions, including budget planning, incentive design, and brand positioning.
ARS Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for severe allergic reactions and anaphylaxis. The company is best known for neffy, an intranasal epinephrine product designed as a needle-free alternative for emergency allergy treatment, and operates in the biotechnology and specialty pharmaceuticals industry.
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Nov 10, 2025
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy
Sep 13, 2025
ARS Pharmaceuticals Reports $72.2 Million U.S. Revenue for neffy® in 2025, Announces Phase 2b CSU Data Expected Mid-2026
3 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ARS Pharmaceuticals.
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly
Oct 1, 2025